39 results about "Specific immune cell" patented technology

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

Methods of analyzing the presence or absence of immune cells capable of binding to an antigen peptide in a sample from one or more individuals are provided. Also provided are methods of detecting or treating cancer or a tumor, a pathogen infection, or an autoimmune disease. A display moiety is provided having particles associated with a plurality of MHC-peptide complexes, where at least two MHC-peptide complexes are different. Also provided are bait compositions having a plurality of display portions and methods of analyzing immune cells by using the display portions or bait compositions as screening tools.

The present invention relates to tumor-specific immune cell markers and their uses. Specifically, an immune cell marker combination is provided, comprising: (1) an immune cell activation marker, and (2) an immune cell inhibition marker, optionally further comprising (3) an intracellular marker, and / or (4) a tissue-resident memory marker. The marker combination of the present invention can more accurately identify and enrich tumor-specific immune cells, and the enriched cell population has better tumor reactivity and tumor killing function.

Multi-specific immune cell engaging molecules are provided herein. These immune cell engaging molecules bind cancer cells co-expressing CD19 and CD33 while also binding immune cells, allowing the immune cells to recognize and destroy the CD19 and CD33-expressing cancer cells.

This disclosure relates to KRAS immunogenic peptides and their uses. According to this disclosure, the KRAS immunogenic peptides selectively bind to MHC class II in a preferential mode to selectively enhance the immunogenicity of specific immune cells capable of killing cancer cells, and thus can be advantageously used as superior cancer vaccines for the prevention and / or treatment of cancer by minimizing immune escape mechanisms of cancer cells.

The invention discloses a marker for predicting ICI treatment related adverse events. According to the application, a disease-specific influencing cell is determined through multi-omics combined analysis, the immune checkpoint inhibitor-related autoimmune encephalopathy can be predicted, and the immune checkpoint inhibitor-related autoimmune encephalopathy can be predicted by evaluating the number of specific immune cells in cerebrospinal fluid of a related patient in the later period.

The present invention provides a modified antigen-specific immune cell that expresses an exogenous CD160 protein. In some embodiments, the modified antigen-specific immune cells further comprise a functional exogenous receptor, such as an engineered TCR or CAR. The present invention also provides methods of modulating CD160 activity in antigen-specific immune cells. The invention also provides methods and pharmaceutical compositions for treating cancer using the modified antigen-specific immune cells described herein and modulators of CD160 activity.

The invention relates to a composition for tumor local injection, a medical and mechanical combined product and application of the composition in preparation of a medicine for tumor local injection administration. The composition comprises an antitumor drug component, an immunologic adjuvant and a drug carrier. By means of the jet flow microneedle delivery device which is specially designed, tumor local drug delivery of anti-tumor drugs can be achieved, and the problem that the maximum drug dosage and the treatment effect are limited due to system toxicity in traditional intravenous drug delivery is solved. The high-concentration local administration of the composition provided by the invention not only improves the local treatment effect of tumors, but also can effectively generate tumor antigens. The tumor antigen generated in situ can be matched with an immunologic adjuvant in the composition to generate tumor specific immune cells on the premise that the immune system of a patient is not damaged due to the toxicity of a drug system, so that the immune response of the local part and the whole body of the patient to tumors is improved. Besides, in the subsequent treatment course after the initial treatment, only the composition of the immunologic adjuvant and the tumor specific polypeptide or the immunologic adjuvant can be given to maintain and enhance the established tumor specific immune response, and accumulated toxicity caused by repeated use of chemotherapeutic drugs is avoided.

Provided herein include new antibodies reactive for canine CD3, which are shown to substantially increase activation of canine T cells; new multi-specific immune cell engager molecules based on the canine CD3 antibodies, which are shown to effectively bind canine cancer antigens and recruit T cells for killing of the cancer cells; as well as new recombinant proteins derived from canine cartilage protein fragments and hydrogels thereof. Uses of these compositions are also provided, which include therapeutic uses of antibodies and multi-specific immune cell engager molecules for treatment of cancers or other diseases in dogs, as well as uses of hydrogels for local immunotherapy delivery for reduction of post-surgical recurrence risk, reduction of cancer at surgically inoperable sites, provision of palliation, and / or substitution for surgery.

To provide methods for selectively modulating the activity of distinct subtypes of cells.SOLUTION: The invention relates to a pseudotyped retrovirus-like particle or retroviral vector comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family, one fused to a cell-targeting domain and the other fused to a functional domain. The invention also relates to the use of the pseudotyped retrovirus-like particle or retroviral vector that selectively modulates a specific subset of cells, in particular activities of specific immune cells. The pseudotyped retrovirus-like particle or retroviral vector is particularly useful for gene therapy, immunotherapy and / or vaccination.SELECTED DRAWING: None

The invention relates to the technical field of tumor treatment, in particular to gel for inducing formation of subcutaneous three-level lymph nodes and application of the gel in tumor treatment. The invention provides a gel for inducing formation of subcutaneous three-level lymph nodes, which is characterized in that a chemotactic factor CCL21 is wrapped in the gel, the surface of the gel is modified with an activated peptide derived from CD40L, the CCL21 can induce immigration of initial T cells and B cells of peripheral blood into the gel and meanwhile induce immigration of antigen presenting cells carrying antigens in tumors, and the formation of the subcutaneous three-level lymph nodes is induced. Therefore, it is ensured that the TLS formed under the skin is tumor-specific. Under the activation action of CD40Lp, various immune cells interact to form T zone and B zone, and finally tumor-specific immune cells are generated to promote anti-tumor immune response.

The present invention relates to an assay for determining the class of gastric adenocarcinoma in a tissue sample using the expression of a gene signature. Specifically, the invention is directed to the utilization of a gene signature in a method to identify and distinguish gastric adenocarcinoma tumors of the "inflamed class", which shows a high tumor immunogenicity and cytotoxicity, enrichment of specific somatic alterations, and increased presence of specific immune cells as well as co-inhibitory receptors, in contrast to the tumors that don't belong to the "inflamed class". Furthermore, the invention also involves methods for making treatment recommendations, estimating a treatment response and predicting prognosis, as well as a kit for carrying out said methods.

The invention discloses an in-vitro amplification method of dog peripheral blood source specific immune cells, and belongs to the technical field of immune cell culture. According to the method, dog peripheral blood serves as a cell source, and efficient amplification of specific immune cells is achieved within 14 days through the steps of lymphocyte separation, immune cell activation, staged density regulation and control culture, culture medium supplementing and the like. By optimizing the combination and concentration of cell factors and accurately regulating and controlling the cell density at different culture stages, the problems of low amplification efficiency, weak specific killing ability, short cell activity maintenance time and the like of the dog immune cells in the prior art are solved. The amplification multiple of the finally obtained specific immune cells can reach 125 times or more, the cell viability is kept 90% or more, the proportion of CD3-NKp46 + phenotype cells exceeds 70%, the application requirements of clinical anti-tumor immune cell preparations can be met, and an efficient and stable cell preparation scheme is provided for dog tumor immunotherapy.

The present invention relates to tumor-specific immune cell markers and their uses. Specifically, an immune cell marker combination is provided, including: (1) an immune cell activation marker, and (2) an immune cell inhibition marker, optionally further including (3) an intracellular marker, and / or (4) a tissue-resident memory marker. The marker combination of the present invention can more accurately identify and enrich tumor-specific immune cells, and the enriched cell population has better tumor reactivity and tumor killing function.

This application discloses a CD4 + T cell-derived tsRNA biomarkers and their applications, wherein the biomarkers are derived from CD4 + A phenylalanine-tRNA fragment from T cells, wherein the phenylalanine-tRNA fragment is 5'tiRNA-36-PheGAA-8, and the nucleotide sequence of the 5'tiRNA-36-PheGAA-8 is shown in SEQ ID NO:5. This application relates to purified pathogenic CD4+ from MG patients. + T cell tsRNA sequencing significantly reduced background noise caused by cellular heterogeneity, providing more reliable data support for elucidating the regulatory mechanisms of tsRNA at the level of specific immune cells, and screening for CD4+ in MG patients. + The abnormally elevated expression of biomarkers in T cells facilitates dynamic monitoring of patients.

According to the identification and application of the cell death and immunosuppression biomarkers of the sepsis patients in different life cycles, transcriptome data of the sepsis patients in different age groups and a normal control group are collected, differential expression gene analysis is performed by utilizing bioinformatics, immune cell infiltration is estimated in combination with a CIBERSORT algorithm, and the cell death and immunosuppression biomarkers of the sepsis patients in different life cycles are identified. And the relation between the DEGs and the specific immune cell subpopulation is discussed through correlation analysis. And taking an intersection with genes related to a programmed cell death mode, constructing a sepsis risk assessment model by using a machine learning algorithm, and quantifying the contribution of the genes to a sepsis prediction result through an SHAP algorithm. The constructed model is especially suitable for neonates, children and adult sepsis patients, can distinguish risk assessment of different age groups and identify key programmed cell death modes, provides new biomarkers and tools for early diagnosis, treatment and risk assessment of sepsis, and is beneficial to improvement of clinical treatment effect and patient prognosis.

The invention discloses an immune cell population function evaluation and screening method based on digital microfluidics, which comprises the following steps: loading a cell suspension containing immune cells to an active matrix digital micro-fluidic chip, and controlling a chip electrode array to carry out on-chip segmentation and dilution on the cell suspension to form a plurality of cell droplets; segmenting a non-specific stimulant or a specific antigen injected into the chip, mixing the segmented non-specific stimulant or specific antigen with the cell droplets in proportion, and performing stimulation incubation; mixing the magnetic beads coated with the cytokine / immunoreaction secretion capture antibody and the enzyme-labeled cytokine / immunoreaction secretion detection antibody, and then mixing and incubating with the cell droplets; carrying out magnetic enrichment on the magnetic beads, and adding fluorescent substrate liquid drops for reaction; fluorescence intensity detection is carried out on the magnetic bead liquid drops, and positive and negative signals are identified, so that negative, strong-positive or weak-positive cell liquid drops after stimulation incubation are distinguished; positioning specific immune response positive cell liquid drops, screening and recycling, and / or continuously diluting and dispersing to complete specific immune cell screening.

The invention provides an immune sensitizer, the immune sensitizer comprises homing cells modified with a nucleic acid aptamer, and the nucleic acid aptamer is used for specifically targeting, recognizing and capturing immune cells. The immune sensitizer can realize selective targeting tumor infiltration and activation of specific immune cells, so that immunotherapy sensitization is realized, tumor suppression is further realized, and the effects of selective infiltration and activation of the immune cells are realized while the immune infiltration efficiency is improved.

An immune cell having membrane-bound IL-21 (mbIL-21), and a preparation method therefor and a use thereof are provided. Specifically, mbIL-21 can be used in immunotherapy. mbIL-21 can enhance the expansion capability and killing power of specific immune cells, thereby enhancing the effect of NK cell therapy.

The present invention relates to anti-VISTA antibody RNA or nucleic acid conjugates (ARC or ANC) for the specific delivery of at least one nucleic acid, such as RNA, into immune cells, and the use of such ARC or ANC as a therapeutic agent, for example for the treatment of autoimmune, allergic and inflammatory disorders, such as autoimmune, allergic and inflammatory disorders. Or for treating cancer and / or for treating inflammatory symptoms associated with cancer caused by a specific immune cell type expressing VISTA.

The present invention relates to a biomarker for predicting therapeutic responsiveness to oral immunotherapy in pediatric patients with food allergies and a method for predicting therapeutic responsiveness to oral immunotherapy using same. As a result of analyzing transcriptomic differences in immune cells of egg allergy patients who have undergone oral immunotherapy, it was confirmed that, after performing oral immunotherapy, the proportion of CD69+ early-activated CD4+ T cells decreased, while the proportions of IKZF2+ Treg cells, HLA-DR+ late-activated CD4+ T cells, and PD-1+ fully activated CD8+ T cells increased, compared to before initiation of oral immunotherapy. Accordingly, the present invention has an effect of accurately predicting therapeutic responsiveness to oral immunotherapy by measuring the proportions of specific immune cells, thereby ensuring the efficiency of oral immunotherapy.

A method of detecting and / or measuring target specific immune cell response to an immune cell target in a sample containing more than one cell, the method comprising the steps of: (a) providing a sample droplet comprising a portion of the sample, wherein the sample droplet is configured to comprise more than one cell but statistically one or less than one immune cell specific for the target; (b) contacting an immune cell target with the sample droplet to form an incubation droplet; and (c) determining the response of a detection agent present in the incubation droplet.

The present invention relates to tumor-specific immune cell markers and their uses. Specifically, an immune cell marker combination is provided, including: (1) an immune cell activation marker, and (2) an immune cell inhibition marker, optionally further including (3) an intracellular marker, and / or (4) a tissue-resident memory marker. The marker combination of the present invention can more accurately identify and enrich tumor-specific immune cells, and the enriched cell population has better tumor reactivity and tumor killing function.

The present invention provides a method for analyzing samples from one or more individuals to determine the presence or absence of immune cells capable of binding to antigen peptides. It also provides a method for detecting or treating cancer or tumors, pathogenic infections, or autoimmune diseases. Further, it provides a display portion having particles to which multiple MHC-peptide complexes are bound, with at least two of the MHC-peptide complexes being distinct. Additionally, it provides a bait composition having multiple display portions, and a method for analyzing immune cells by using the display portions or the bait composition as a screening tool.

A conjugate of formula EVTsmL-L-AMRL, wherein EVTsmL is an enveloped virus-targeting, small molecule ligand, AMRL is an activated macrophage-recruiting ligand, and L is a linker that is covalently bound to EVTsmL and AMRL; a composition comprising the same; and a method of using the conjugate or composition to treat (therapeutically or prophylactically) a viral infection.

The invention discloses a pig immune state evaluation method based on a cell specific gene co-expression module. The method comprises the following steps: S1, key module determination: pre-determining a key gene co-expression module significantly associated with pig core immune traits; the key gene co-expression module comprises at least one first module which is selected from a neutrophil transcriptome and is remarkably and positively correlated with the percentage of neutrophil, and at least one second module which is selected from a peripheral blood mononuclear cell transcriptome and is remarkably and positively correlated with the percentage of lymphocyte; and S2, an immune state evaluation step: evaluating the immune state of the to-be-tested pig. Compared with the prior art, the invention has the following beneficial effects: cell specificity: specific immune cells are separated for transcriptome analysis, specific expression signals of neutrophils and PBMCs are accurately captured, the problem of mixed signals of whole blood sequencing is overcome, and evaluation is more targeted and accurate;

Compositions, methods, and kits are provided for diagnosing bacterial infections that distinguish tissue infected with dormant bacteria from uninfected tissue. In particular, the subject methods can be used to detect dormant bacteria, including bacteria in biofilms on joint replacement implants by measuring biomarkers in synovial fluid or blood or analyzing specific immune cell types, including regulatory T-cells, natural killer cells, monocytes, plasmacytoid dendritic cells, or myeloid dendritic cells within a periarticular tissue sample in contact with the effective joint space of an implant.

The invention belongs to the technical field of immunity, and discloses a CpG ODN delivery system based on dextran capsule aluminum salt particles and a preparation method and application thereof. The CpG ODN delivery system comprises dextran particles GPs from yeast, an aluminum salt colloid encapsulated in cavities of the dextran particles GPs, and oligodeoxynucleotide CpG ODN adsorbed on the aluminum salt colloid through static electricity. According to the system, the immune activation effect of CpG ODN on specific immune cells such as DC is remarkably improved, so that stronger antigen-specific humoral immunity and cellular immune response is induced. The system is highly simple and convenient to operate, highly uniform in particle size and relatively safe in component, and an important innovative scheme is provided for promoting application of CpG ODN in vaccine research and development.

The invention discloses a method for establishing a stage II-III colorectal cancer postoperative recurrence and metastasis prediction model, and belongs to the technical field of biomedicine. The method comprises the following steps: collecting a postoperative tumor tissue sample of a II-III stage colorectal cancer patient, and staining specific immune cells in the colorectal cancer tissue sample by adopting an immunohistochemical technology; and then calculating the average infiltration count of the immune cells, defining a prognostic index according to a specific formula, dividing the II-III stage colorectal cancer patients into a high-risk group and a low-risk group after operation by taking a median of the prognostic index as a cutoff value, and constructing a II-III stage colorectal cancer postoperative recurrence and metastasis prediction model based on the prognostic index. The traditional staging limitation is broken through, the tumor immune microenvironment is focused, specific immune cells are detected, the prognosis index is quantified and constructed, the median of the prognosis index is taken as a truncation value, patients are divided into a high-risk group and a low-risk group, the recurrence and metastasis risk of the high-risk group is large, and the risk of the low-risk group is small. Therefore, a prediction model is constructed, and a doctor is helped to formulate a personalized treatment scheme.